The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

@article{Buske2009TheAO,
  title={The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)},
  author={Christian Buske and Eva Hoster and Martin P Dreyling and Hartmut Eimermacher and Hannes Wandt and Bernd Metzner and Roland J. Fuchs and J{\"o}rg Bittenbring and Bernhard Josef W{\"o}rmann and Karin Hohloch and G. Hess and W. -D. Ludwig and J{\"o}rg Schimke and Stefan Schmitz and Michael Kneba and Marcel Reiser and Ullrich Graeven and Wolfram Klapper and Michael Unterhalt and Wolfgang Hiddemann},
  journal={Leukemia},
  year={2009},
  volume={23},
  pages={153-161}
}
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Current status and perspective of antibody therapy in follicular lymphoma

  • G Lenz, M Dreyling, E Hoster, B Wormann, U Duhrsen, B Metzner
  • Haematologica
  • 2006

Similar Papers

Loading similar papers…